NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Drug candidate shows potential to stop progression of sepsis

By Mindo - 25th Mar 2019

Research into a new breakthrough therapy for sepsis has shown it has potential to stop sepsis-causing bacteria from triggering organ damage in the early stages of the condition. The pre-clinical trial of InnovoSep, carried out by researchers at RCSI, has demonstrated that the drug also has the potential to stop progression of sepsis to multiple organ failure in the later stages. The research was presented at the recent RCSI Research Day 2019 by Dr Sinéad Hurley, a Postdoctoral Fellow at the School of Pharmacy and Irish Centre for Vascular Biology.
Pictured with Dr Hurley is Principal Investigator Prof Steve Kerrigan, Associate Professor of Pharmacology in the School of Pharmacy and Head of the Cardiovascular Infection Research Group at the Irish Centre for Vascular Biology.

Leave a Reply

Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read